艾贝格司亭α对实体肿瘤患者化疗相关中性粒细胞减少症的预防效果分析  

Preventive effect of Ebergstimαon chemotherapy-related neutropenia in patients with solid tumors

作　　者：喻敬涛 Yu Jing-tao(Department of Hematology and Oncology,Guangshan People's Hospital,Xinyang 465499,Henan,China)

机构地区：[1]光山县人民医院血液肿瘤科,河南信阳465499

出　　处：《四川生理科学杂志》2025年第4期881-883,共3页

摘　　要：目的:探究实体肿瘤患者使用艾贝格司亭α注射液对化疗引发的中性粒细胞减少症(Chemotherapy-induced Neutropenia,CIN)的预防效果及安全性。方法:选取2023年8月到2024年8月期间本院血液肿瘤科收治的60例化疗后的实体肿瘤患者作为研究对象。采用随机数字表法将患者分为对照组和研究组,每组各30例。对照组化疗后预防性应用硫培非格司亭治疗,观察组化疗后预防性应用艾贝格司亭α注射液。分析比较两组的治疗效果,化疗期间CIN发生率及持续时间以及药物应用期间不良事件发生情况。结果:化疗3 w后,研究组的白细胞计数(White Blood Cells,WBC)和中性粒细胞计数(Absolute neutrophil count,ANC)的减少时间、恢复时间均较对照组显著缩短,维持时间均较对照组显著延长(P<0.05)。两组化疗期间CIN发生率比较无显著差异(P>0.05),但研究组的CIN持续时间比对照组显著缩短(P<0.05)。化疗期间,研究组的药物相关不良反应发生率较对照组显著降低(P<0.05)。结论:预防性应用艾贝格司亭α注射液可实现实体肿瘤患者化疗相关CIN发生的良好控制,提升治疗效果,减少药物相关不良事件发生。Objective:To investigate the preventive effect and safety of ebeginstineαinjection for Chemotherapy-induced Neutropenia(CIN)in patients with solid tumors.Methods:From August 2023 to August 2024,60 patients with solid tumors after chemotherapy in the Department of Hematology and Oncology of our hospital were selected as the study objects.The patients were divided into control group and study group with 30 cases in each group by random number table method.The control group was prophylactically treated with tiopefegrasstim after chemotherapy,and the observation group was prophylactically treated with ebergstimαinjection after chemotherapy.The therapeutic effect,incidence and duration of CIN during chemotherapy and adverse events during drug use were analyzed and compared between the two groups.Results:After 3 weeks of chemotherapy,the reduction time and recovery time ofWBC and ANC in the study group were significantly shorter than those in the control group,and the maintenance time was significantly prolonged(P<0.05).There was no significant difference in the incidence of CIN during chemotherapy between the two groups(P>0.05),but the duration of CIN in the study group was significantly shorter than that in the control group(P<0.05).During chemotherapy,the incidence of drug-related adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion:The prophylactic application of ebeginstineαinjection can achieve a good control of chemotherapy-related CIN in solid tumor patients,improve the therapeutic effect,and reduce the occurrence of drug-related adverse events.

关 键 词：实体肿瘤 中性粒细胞减少症 化疗 硫培非格司亭 艾贝格司亭α 

分 类 号：R730.5[医药卫生—肿瘤]